RAHUL BANERJEE, MD, FACP
CONTACT INFORMATION
Email addresses: rahul.banerjee.md@gmail.com / rahulban@uw.edu
Work address: 825 Eastlake Ave East, J4-419, Seattle, WA 98109
Home address: 1145 Republican St Apt 2307, Seattle, WA 98109
Telephone: 206-606-1453 (office) / 203-654-0360 (cell)
Social media: @RahulBanerjeeMD (Twitter / X)
ACADEMIC APPOINTMENTS
Assistant Professor, Clinical Research Division
Fred Hutchinson Cancer Center, Seattle, WA 2022 – present
TOP 3 PEER-REVIEWED MANUSCRIPTS (N=120 ALTOGETHER)
Original research
3. Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, Atrash S, Bachanova V,
Beitinjaneh AM, Bhurtel E, Puglianini OC, Chhabra S, Cicero KI, Davis JA, Dhakal B, Dima D,
Ferreri CJ, Forsberg PA, Freeman CL, Herr MM, Jain T, Janakiram M, Khouri J, Kocoglu MH,
Kumar A, Liu Y, Locke F, McGuirk JP, Mikkilineni L, Nadeem O, Parrondo RD, Pasvolsky OP,
Peres LC, Purvey S, Raza S, Reshef R, Richard R, Rossi AC, Sborov DW, Shune L, Wagner
CB, Zanwar SS, Sidana S, Patel KK, Hansen DK, Kumar SK, Lin Y, Martin TG, Voorhees PM,
Anderson LD, Cowan AJ, Kaur G. Universal driving restrictions beyond 4 weeks appear
unnecessary following CAR-T therapy in multiple myeloma. Blood Advances. 2025; 9(9): 2336-
2340.
2. Banerjee R, Fritz AR, Akhtar OS, Freeman CL, Cowan AJ, Shah N, Landau HJ, Kumar SK, Vogl
DT, Efebera YA, McCarthy PL, Vesole DH, Mendizabal A, Krishnan AY, Somlo G, Stadtmauer
EA, Pasquini MC. Urine-free response criteria predict progression-free survival in multiple
myeloma: a post hoc analysis of BMT CTN 0702. Leukemia. 2025; 39(4): 1001-1004.
1. Banerjee R, Sexton R, Cowan AJ, Rosenberg AS, Ailawadhi S, Rajkumar SV, Kumar SK,
Dispenzieri A, Lonial S, Durie BGM, Richardson PG, Usmani SZ, Hoering A, Orlowski RZ.
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma:
a secondary SWOG analysis. Blood. 2025; 145(1):75-84.
SELECTED AD HOC PEER REVIEW POSITIONS
** New England Journal of Medicine 2026 – present
** Blood 2024 – present
** Journal of Clinical Oncology (JCO) 2024 – present
** Nature Medicine 2024 – present
** Leukemia 2023 – present
GUIDELINE-RELATED COMMITTEES
ACR Appropriateness Criteria – Multiple Myeloma
American College of Radiology, Reston, VA 2026 – present
Guidelines for cytogenetic reporting in multiple myeloma
Cancer Genomics Consortium (Plasma Cell Working Group), Lafayette, LA 2024 – 2025
ASCO guidelines for the treatment of multiple myeloma
American Society of Clinical Oncology (ASCO), Alexandria, VA 2024 – 2025
